In line with previous clinical trial findings, real-world data show that bevacizumab improves outcomes in patients with ...

Patients with high-risk advanced ovarian cancer obtained a marginal survival benefit with the addition of bevacizumab ...

A real-world study based on information from an electronic health records–derived database reveals limited benefits of adding ...

The addition of bevacizumab to first-line (1L) chemotherapy offers real-world benefit to patients with epithelial ovarian ...

Maintenance with niraparib and bevacizumab can be effective in patients with platinum-sensitive, recurrent ovarian cancer previously treated with a PARP inhibitor.

given on top of standard first-line therapy with chemotherapy and bevacizumab for newly-diagnosed advanced ovarian cancer. While Lynparza is already used to treat BRCA-positive ovarian cancer ...

Discover "Bevacizumab - Biosimilar Insight, 2025," which analyzes 25+ companies and 30+ drugs in the bevacizumab biosimilars landscape. The report covers marketed drugs, pipeline molecules, and ...

cervical cancer, and epithelial ovarian, fallopian tube, and primary peritoneal cancers. Approved in 2021 in both Canada and Europe, Biocon’s bevacizumab biosimilar is already available in both ...

Turning pain into purpose is the aim of a Northland ovarian cancer patient, who hopes a song about her cancer fight will ...

The BELLA phase 2 clinical trial of relacorilant plus nab-paclitaxel and Avastin among patients with platinum-resistant ovarian cancer has been launched. Treatment with a CAR-M cell therapy plus ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...